Developping innovative kits for the ADME-Tox segment since 2011

What We Do

p96 plates

ReadyCell develops, implements and commercializes new innovative kits through strategic partnership with other emerging market players: biotechnological, pharmaceutical and medical devices companies as well as research centres.

Our products provide robust and reliable results in a fast and efficient manner, reducing user’s time and costs, and allowing pharmaceutical and biotech companies to use human and material resources more efficiently, while optimizing the development cycle for new drugs.

Our R&D department works intensively in the expansion of our product portfolio, with the aim of developing new tools that fulfil the needs of the pharmaceutical industry. By offering a diversity of R&D service, we put at the industry disposal our expertise, know-how, technical & human resources to develop ad hoc solutions according to their specific needs.

Where We Come From

In 2010, Advancell’s alternative testing unit is segregated from the core company, as part of a new business strategy aimed to refocus the company’s activity into the nano medicine and drug development fields.

At that time, Leitat was intensively involved in increasing its portfolio of services and products within the biotechnology and biomedicine field.

Thus, ReadyCell was established in 2011 as a joint venture, equally owned by Advancell and Leitat aimed to develop and commercialize cell-based reagents and offer R&D services in the field ADME-Tox. This corporate operation allowed to combine the vast know-how and expertise, along with technical and human resources of two entities in the biotechnology field, and take advantage of synergies, to create a highly competitive company aimed to:

  • Improve and commercialize the product portfolio of Advancell’s alternative testing unit
  • Initiate new research projects to develop new kits and services

Since 2014, ReadyCell is fully part of Leitat’s structure and the company completely integrated its R&D and commercial activities. This enabled ReadyCell to develop more complex projects, to concentrate commercial and communication efforts and thus to be more effective. ReadyCell can in turn offer the highest quality service to its customers in the field of in vitro ADME assays.

Leitat Terrassa